Shopping Cart 0
Cart Subtotal
USD 0

MacroGenics Inc (MGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

MacroGenics Inc (MacroGenics) is a clinical-stage biopharmaceutical company which focuses on the discovery, development and delivery of novel antibody-based therapeutics for the treatment of cancer, infectious diseases and autoimmune disorders. Its pipeline includes product candidates for the treatment of solid tumors, breast and gastroesophageal cancers type 1 diabetes, HIV, leukemia; and DART product candidates for the treatment of acute myeloid leukemia and myelodysplastic syndrome; colorectal cancer; and b-cell malignancies. The company's product candidates are based on three core proprietary technology platforms, namely, Cancer Stem Cell Platform, Dual-Affinity Re-Targeting (or DART) and TRIDENT Platform and Fc Optimization Platform. It also works in collaboration with major pharmaceutical and biotechnology companies to leverage its technology platforms and protein engineering capabilities to develop product candidates. MacroGenics is headquartered in Rockville, Maryland, the US.

MacroGenics Inc (MGNX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MacroGenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

MacroGenics Inc, Medical Devices Deals, 2012 to YTD 2018 10

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

MacroGenics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Private Equity 12

Mirae Asset Global Investments Acquires 5% Stake in MacroGenics 12

Partnerships 13

MacroGenics Enters into Agreement with Merck 13

MacroGenics Enters into Co-Development Agreement with Takeda Pharma 14

Takeda Pharma Enters Option Agreement with MacroGenics for MGD010 15

Licensing Agreements 17

Provention Bio Enters into Licensing Agreement with MacroGenics for PRV-3279 17

Roche Enters into Licensing Agreement with MacroGenics 18

Incyte Enters into Licensing Agreement with MacroGenics 19

MacroGenics Enters into Licensing Agreement with Synthon Biopharma 20

Janssen Biotech Enters into Licensing Agreement with MacroGenics for MGD015 21

MacroGenics Exercised Option For Licensing Agreement With Servier For DART Products 22

MacroGenics Enters Into Licensing Agreement With Gilead Sciences For DART Technology 24

Equity Offering 26

MacroGenics Raises USD110 Million in Public Offering of Shares 26

Macrogenics Plans to Raise up to USD75 Million in Public Offering of Shares 28

Macrogenics Raises USD23.7 Million in Private Placement of Shares 29

MacroGenics Raises USD150 Million in Public Offering of Shares 30

MacroGenics Raises USD75 Million in Private Placement of Common Stock 32

MacroGenics Completes Public Offering Of Shares For USD 82 Million 34

MacroGenics Completes IPO For USD 92 Million 36

Asset Transactions 38

Provention Bio Acquires PRV-031 from MacroGenics 38

MacroGenics Inc-Key Competitors 39

MacroGenics Inc-Key Employees 40

MacroGenics Inc-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 42

Financial Announcements 42

Nov 07, 2018: MacroGenics provides update on corporate progress and 3rd quarter 2018 financial results 42

Aug 07, 2018: MacroGenics provides update on corporate progress and 2nd quarter 2018 financial results 44

May 07, 2018: MacroGenics Provides Update on Corporate Progress and 1st Quarter 2018 Financial Results 46

Feb 27, 2018: MacroGenics Reports 2017 Financial Results 48

Nov 08, 2017: MacroGenics Provides Update on Corporate Progress and Third Quarter 2017 Financial Results 50

Aug 02, 2017: MacroGenics Provides Update on Corporate Progress and Second Quarter 2017 Financial Results 52

May 03, 2017: MacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results 54

Feb 28, 2017: MacroGenics Provides Update on Corporate Progress and 2016 Financial Results 56

Corporate Communications 58

Nov 15, 2017: MacroGenics Names Dr. Jay Siegel to its Board of Directors 58

Jan 25, 2017: MacroGenics Announces Appointments to Board of Directors 59

Product News 60

11/10/2017: MacroGenics To Present Poster on MGD019 at 32nd Annual SITC Meeting 2017 60

09/05/2017: MacroGenics Provides Update on its DART candidate MGD013 61

Product Approvals 62

Sep 05, 2017: MacroGenics Advances Development of its DART candidate MGD014 62

Jan 05, 2017: MacroGenics' MGD006 Granted Orphan Drug Status for AML by FDA 63

Clinical Trials 64

Nov 10, 2017: MacroGenics Announces Poster Presentations on MGD013 at 32nd Annual SITC Meeting 2017 64

Sep 10, 2017: Phase 1 Data for Flotetuzumab, MacroGenics CD123 x CD3 DART Molecule, Presented at ESMO Congress 2017 65

Jul 17, 2017: Phase 1 Data for Flotetuzumab, MacroGenics CD123 x CD3 DART Molecule, Accepted for Oral Presentation at ESMO Congress 2017 66

Appendix 67

Methodology 67

About GlobalData 67

Contact Us 67

Disclaimer 67


List Of Figure

List of Figures

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

MacroGenics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

MacroGenics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MacroGenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MacroGenics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

MacroGenics Inc, Medical Devices Deals, 2012 to YTD 2018 10

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Mirae Asset Global Investments Acquires 5% Stake in MacroGenics 12

MacroGenics Enters into Agreement with Merck 13

MacroGenics Enters into Co-Development Agreement with Takeda Pharma 14

Takeda Pharma Enters Option Agreement with MacroGenics for MGD010 15

Provention Bio Enters into Licensing Agreement with MacroGenics for PRV-3279 17

Roche Enters into Licensing Agreement with MacroGenics 18

Incyte Enters into Licensing Agreement with MacroGenics 19

MacroGenics Enters into Licensing Agreement with Synthon Biopharma 20

Janssen Biotech Enters into Licensing Agreement with MacroGenics for MGD015 21

MacroGenics Exercised Option For Licensing Agreement With Servier For DART Products 22

MacroGenics Enters Into Licensing Agreement With Gilead Sciences For DART Technology 24

MacroGenics Raises USD110 Million in Public Offering of Shares 26

Macrogenics Plans to Raise up to USD75 Million in Public Offering of Shares 28

Macrogenics Raises USD23.7 Million in Private Placement of Shares 29

MacroGenics Raises USD150 Million in Public Offering of Shares 30

MacroGenics Raises USD75 Million in Private Placement of Common Stock 32

MacroGenics Completes Public Offering Of Shares For USD 82 Million 34

MacroGenics Completes IPO For USD 92 Million 36

Provention Bio Acquires PRV-031 from MacroGenics 38

MacroGenics Inc, Key Competitors 39

MacroGenics Inc, Key Employees 40

MacroGenics Inc, Other Locations 41

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

MacroGenics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

MacroGenics Inc (MacroGenics) is a clinical-stage biopharmaceutical company which focuses on the discovery, development and delivery of novel antibody-based therapeutics for the treatment of cancer, infectious diseases and autoimmune disorders. Its pipeline includes product candidates for the treatment of solid tumors, breast and gastroesophageal cancers type 1 diabetes, HIV, leukemia; and DART product candidates for the treatment of acute myeloid leukemia and myelodysplastic syndrome; colorectal cancer; and b-cell malignancies. The company's product candidates are based on three core proprietary technology platforms, namely, Cancer Stem Cell Platform, Dual-Affinity Re-Targeting (or DART) and TRIDENT Platform and Fc Optimization Platform. It also works in collaboration with major pharmaceutical and biotechnology companies to leverage its technology platforms and protein engineering capabilities to develop product candidates. MacroGenics is headquartered in Rockville, Maryland, the US.

MacroGenics Inc (MGNX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MacroGenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

MacroGenics Inc, Medical Devices Deals, 2012 to YTD 2018 10

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

MacroGenics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Private Equity 12

Mirae Asset Global Investments Acquires 5% Stake in MacroGenics 12

Partnerships 13

MacroGenics Enters into Agreement with Merck 13

MacroGenics Enters into Co-Development Agreement with Takeda Pharma 14

Takeda Pharma Enters Option Agreement with MacroGenics for MGD010 15

Licensing Agreements 17

Provention Bio Enters into Licensing Agreement with MacroGenics for PRV-3279 17

Roche Enters into Licensing Agreement with MacroGenics 18

Incyte Enters into Licensing Agreement with MacroGenics 19

MacroGenics Enters into Licensing Agreement with Synthon Biopharma 20

Janssen Biotech Enters into Licensing Agreement with MacroGenics for MGD015 21

MacroGenics Exercised Option For Licensing Agreement With Servier For DART Products 22

MacroGenics Enters Into Licensing Agreement With Gilead Sciences For DART Technology 24

Equity Offering 26

MacroGenics Raises USD110 Million in Public Offering of Shares 26

Macrogenics Plans to Raise up to USD75 Million in Public Offering of Shares 28

Macrogenics Raises USD23.7 Million in Private Placement of Shares 29

MacroGenics Raises USD150 Million in Public Offering of Shares 30

MacroGenics Raises USD75 Million in Private Placement of Common Stock 32

MacroGenics Completes Public Offering Of Shares For USD 82 Million 34

MacroGenics Completes IPO For USD 92 Million 36

Asset Transactions 38

Provention Bio Acquires PRV-031 from MacroGenics 38

MacroGenics Inc-Key Competitors 39

MacroGenics Inc-Key Employees 40

MacroGenics Inc-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 42

Financial Announcements 42

Nov 07, 2018: MacroGenics provides update on corporate progress and 3rd quarter 2018 financial results 42

Aug 07, 2018: MacroGenics provides update on corporate progress and 2nd quarter 2018 financial results 44

May 07, 2018: MacroGenics Provides Update on Corporate Progress and 1st Quarter 2018 Financial Results 46

Feb 27, 2018: MacroGenics Reports 2017 Financial Results 48

Nov 08, 2017: MacroGenics Provides Update on Corporate Progress and Third Quarter 2017 Financial Results 50

Aug 02, 2017: MacroGenics Provides Update on Corporate Progress and Second Quarter 2017 Financial Results 52

May 03, 2017: MacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results 54

Feb 28, 2017: MacroGenics Provides Update on Corporate Progress and 2016 Financial Results 56

Corporate Communications 58

Nov 15, 2017: MacroGenics Names Dr. Jay Siegel to its Board of Directors 58

Jan 25, 2017: MacroGenics Announces Appointments to Board of Directors 59

Product News 60

11/10/2017: MacroGenics To Present Poster on MGD019 at 32nd Annual SITC Meeting 2017 60

09/05/2017: MacroGenics Provides Update on its DART candidate MGD013 61

Product Approvals 62

Sep 05, 2017: MacroGenics Advances Development of its DART candidate MGD014 62

Jan 05, 2017: MacroGenics' MGD006 Granted Orphan Drug Status for AML by FDA 63

Clinical Trials 64

Nov 10, 2017: MacroGenics Announces Poster Presentations on MGD013 at 32nd Annual SITC Meeting 2017 64

Sep 10, 2017: Phase 1 Data for Flotetuzumab, MacroGenics CD123 x CD3 DART Molecule, Presented at ESMO Congress 2017 65

Jul 17, 2017: Phase 1 Data for Flotetuzumab, MacroGenics CD123 x CD3 DART Molecule, Accepted for Oral Presentation at ESMO Congress 2017 66

Appendix 67

Methodology 67

About GlobalData 67

Contact Us 67

Disclaimer 67


List Of Figure

List of Figures

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

MacroGenics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

MacroGenics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MacroGenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MacroGenics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

MacroGenics Inc, Medical Devices Deals, 2012 to YTD 2018 10

MacroGenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Mirae Asset Global Investments Acquires 5% Stake in MacroGenics 12

MacroGenics Enters into Agreement with Merck 13

MacroGenics Enters into Co-Development Agreement with Takeda Pharma 14

Takeda Pharma Enters Option Agreement with MacroGenics for MGD010 15

Provention Bio Enters into Licensing Agreement with MacroGenics for PRV-3279 17

Roche Enters into Licensing Agreement with MacroGenics 18

Incyte Enters into Licensing Agreement with MacroGenics 19

MacroGenics Enters into Licensing Agreement with Synthon Biopharma 20

Janssen Biotech Enters into Licensing Agreement with MacroGenics for MGD015 21

MacroGenics Exercised Option For Licensing Agreement With Servier For DART Products 22

MacroGenics Enters Into Licensing Agreement With Gilead Sciences For DART Technology 24

MacroGenics Raises USD110 Million in Public Offering of Shares 26

Macrogenics Plans to Raise up to USD75 Million in Public Offering of Shares 28

Macrogenics Raises USD23.7 Million in Private Placement of Shares 29

MacroGenics Raises USD150 Million in Public Offering of Shares 30

MacroGenics Raises USD75 Million in Private Placement of Common Stock 32

MacroGenics Completes Public Offering Of Shares For USD 82 Million 34

MacroGenics Completes IPO For USD 92 Million 36

Provention Bio Acquires PRV-031 from MacroGenics 38

MacroGenics Inc, Key Competitors 39

MacroGenics Inc, Key Employees 40

MacroGenics Inc, Other Locations 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

MacroGenics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.